European Union Approves Axumin as Imaging Agent for Detecting Prostate Cancer Recurrences

European Union Approves Axumin as Imaging Agent for Detecting Prostate Cancer Recurrences
The European Union has granted marketing authorization to Axumin, an injectable radioactive agent used to detect prostate cancer that has recurred. High levels or PSA, or prostate specific antigen in blood, can signal the return of prostate cancer. One way doctors can confirm a recurrence is using positron emission tomography, or PET scans, to try to spot it. Axumin, developed by Blue Earth Diagnostics, helps physicians who perform a scan detect high amino acid levels that can indicate a recurrence. The U.S. Food and Drug Administration approved Axumin as a PET imaging agent for detecting prostate cancer recurr
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *